Immunotherapy in SCLC: Challenges and Opportunities of Rapidly Evolving Treatments

Join us for this dynamic, CME-certified symposium where lung cancer experts Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, will review the evolving role of immunotherapy in the treatment of small-cell lung cancer, including patient case discussions and discussion of new data from the 2020 ASCO Virtual Scientific Meeting.

Sign up now!

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “Immunotherapy in SCLC: Challenges and Opportunities of Rapidly Evolving Treatments” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that each Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Immune Checkpoint Inhibitor Therapy in the Clinical Management of SCLC: Introduction – Anna F. Farago, MD, PhD

Applying Immune Checkpoint Inhibitor Therapy in the Clinical Management of SCLC – Taofeek K. Owonikoko, MD, PhD

  • Review of key clinical trial data
  • Patient case discussion: newly diagnosed ES-SCLC

Immune Checkpoint Inhibitor Therapy in the Clinical Management of Pretreated ES-SCLC – Anna F. Farago, MD, PhD

  • Review of key clinical trial data
  • Identifying and managing irAEs
  • Patient case discussion: pretreated ES-SCLC

Exploring the Next Frontier for Immune Checkpoint Inhibitors Combinations in SCLC – Taofeek K. Owonikoko, MD, PhD

  • Evolving role of biomarker assessment
  • Ongoing clinical trials of checkpoint inhibitors for LS-SCLC and ES-SCLC
  • Other therapies in development

Final Panel Discussion and Audience Question and Answer Session: Clinical Pearls for Optimal Application of Immune Checkpoint Inhibitors in the Clinic



Date / Time
Event Details


Anna Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Taofeek Owonikoko, MD, PhD

Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate immune checkpoint inhibitors into the treatment of patients with SCLC.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the role of combination approaches to optimize checkpoint inhibitor efficacy and reduce treatment resistance in patients with SCLC
  • Plan treatment strategies for patients with extensive-stage SCLC that include immune checkpoint inhibitor combinations
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor combinations in SCLC
  • Manage immune-related adverse events in patients with advanced SCLC receiving immune checkpoint inhibitor therapy
  • Incorporate investigational immunotherapy-based combinations and clinical trial participation as part of clinical care strategies for patients with SCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.